Abstract
Aim
To evaluate the impact of postmenopausal osteoporosis on thiol/disulfide homeostasis.
Materials and methods
A total of 75 participants were divided into two groups: Group 1 (n = 40) was composed of healthy postmenopausal women, and group 2 (n = 35) was composed of women with postmenopausal osteoporosis. Clinical findings and thiol/disulfide homeostasis were compared between the two groups.
Results
The disulfide/native thiol ratio was 8.6% ± 3.6 in group 1 and 12.7% ± 8.4 in group 2 (p = 0.04). The disulfide/native thiol percent ratio was significantly higher in group 2 after adjustment for the years since menopause and age (p < 0.05). The native thiol/total thiol percent ratio was 85.6% ± 4.8 in group 1 and 73.8% ± 24.9 in group 2 (p = 0.01). The native thiol/total thiol percent ratio was significantly lower in group 2 after adjustment for the years since menopause and age (p < 0.05).
Conclusion
Thiol/disulfide homeostasis shifted to the disulfide side independent of age and years since menopause in postmenopausal osteoporosis.
Similar content being viewed by others
References
Mendoza N, Sanchez-Borrego R, Villero J et al (2013) 2013 Up-date of the consensus statement of the Spanish Menopause Society on postmenopausal osteoporosis. Maturitas 76:99–107
Ishtiaq S, Fogelman I, Hampson G (2015) Treatment of post-menopausal osteoporosis: beyond bisphosphonates. J Endocrinol Invest 38(1):13–29. doi:10.1007/s40618-014-0152-z
Vescini F, Attanasio R, Balestrieri A, Bandeira F, Bonadonna S, Camozzi V, Cassibba S, Cesareo R, Chiodini I, Francucci CM, Gianotti L, Grimaldi F, Guglielmi R, Madeo B, Marcocci C, Palermo A, Scillitani A, Vignali E, Rochira V, Zini M (2016) Italian association of clinical endocrinologists (AME) position statement: drug therapy of steoporosis. J Endocrinol Invest 39(7):807–834
Cairoli E, Zhukouskaya VV, Eller-Vainicher C, Chiodini I (2015) Perspectives on osteoporosis therapies. J Endocrinol Invest 38(3):303–311
Altindag O, Erel O, Soran N, Celik H, Selek S (2008) Total oxidative/anti-oxidative status and relation to bone mineral density in osteoporosis. Rheumatol Int 28(4):317–321
Manolagas SC (2010) From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr Rev 31:266–300
Turell L, Radi R, Alvarez B (2013) The thiol pool in human plasma: the central contribution of albumin to redox processes. Free Radic Biol Med 65:244–253
Eren Y, Dirik E, Nes¸eliog ˘lu S et al (2015) Oxidative stress and decreased thiol level in patients with migraine: cross-sectional study. Acta Neurol Belg 115:643–649
Jones DP, Liang Y (2009) Measuring the poise of thiol/disulfide couples in vivo. Free Radic Biol Med 47:1329–1338
Korkmaz V, Kurdoglu Z, Alisik M, Cetin O, Korkmaz H, Surer H, Erel O (2016) Impairment of thiol-disulfide homeostasis in preeclampsia. J Matern Fetal Neonatal Med 3:1–6
Bektas H, Vural G, Gumusyayla S, Deniz O, Alisik M, Erel O (2016) Dynamic thiol-disulfide homeostasis in acute ischemic stroke patients. Acta Neurol Belg 116(4):489–494
Ates I, Kaplan M, Yuksel M, Mese D, Alisik M, Erel Ö, Yilmaz N, Guler S (2016) Determination of thiol/disulphide homeostasis in type 1 diabetes mellitus and the factors associated with thiol oxidation. Endocrine 51(1):47–51
Genant HK, Cooper C, Poor G, Reid I, Ehrlich G, Kanis J et al (1999) Interim report and recommendations of the World Health Organization task-force for osteoporosis. Osteoporos Int 10:259–264
Erel O, Neselioglu S (2014) A novel and automated assay for thiol/disulfide homeostasis. Clin Biochem. doi:10.1016/j.clinbiochem.2014.09.026
Mlakar SJ, Osredkar J, Prezelj J, Marc J (2012) Antioxidant enzymes GSR, SOD1, SOD2, and CAT gene variants and bone mineral density values inpostmenopausal women: a genetic association analysis. Menopause 19(3):368–376
Sendur OF, Turan Y, Tastaban E, Serter M (2009) Antioxidant status in patients with osteoporosis: a controlled study. Joint Bone Spine 76(5):514–518
Wu Q, Zhong ZM, Pan Y, Zeng JH, Zheng S, Zhu SY, Chen JT (2015) Advanced oxidation protein products as a novel marker of oxidative stress in postmenopausal osteoporosis. Med Sci Monit 21:2428–2432
Zhong ZM, Bai L, Chen JT (2009) Advanced oxidation protein products inhibit proliferation and differentiation of rat osteoblast-like cells via NF-kappaB pathway. Cell Physiol Biochem 24:105–114
Sun N, Yang L, Li Y, Zhang H, Chen H, Liu D, Li Q, Cai D (2013) Effect of advanced oxidation protein products on the proliferation and osteogenic differentiation of rat mesenchymal stem cells. Int J Mol Med 32(2):485–491. doi:10.3892/ijmm.2013.1402
Zeng JH, Zhong ZM, Li XD, Wu Q, Zheng S, Zhou J, Ye WB, Xie F, Wu XH, Huang ZP, Chen JT (2014) Advanced oxidation protein products accelerate bone deterioration in aged rats. Exp Gerontol 50:64–71
D’Erasmo E, Pisani D, Ragno A, Raejntroph N, Letizia C, Acca M (1999) Relationship between serum albumin and bone mineral density in postmenopausal women and in patients with hypoalbuminemia. Horm Metab Res 31(6):385–388
Afshinnia F, Wong KK, Sundaram B, Ackermann RJ, Pennathur S (2016) Hypoalbuminemia and osteoporosis: reappraisal of a controversy. J Clin Endocrinol Metab 101(1):167–175
Kirlin WG, Cai J, Thompson SA, Diaz D, Kavanagh TJ, Jones DP (1999) Glutathione redox potential in response to differentiation and enzyme inducers. Free Radic Biol Med 27(11–12):1208–1218
Nkabyo YS, Ziegler TR, Gu LH, Watson WH, Jones DP (2002) Glutathione and thioredoxin redox during differentiation in human colon epithelial (Caco-2) cells. Am J Physiol Gastrointest Liver Physiol 283(6):G1352–G1359
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors report that they have no conflicts of interest.
Ethical approval
Ethics committee approval was received for this study.
Informed consent
Written informed consent was obtained from all the women who participated in this study.
Rights and permissions
About this article
Cite this article
Korkmaz, V., Kurdoglu, Z., Alisik, M. et al. Thiol/disulfide homeostasis in postmenopausal osteoporosis. J Endocrinol Invest 40, 431–435 (2017). https://doi.org/10.1007/s40618-016-0585-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40618-016-0585-7